Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Dynamic functional connectivity in schizophrenia and autism spectrum disorder: Convergence, divergence and classification.

Rabany L, Brocke S, Calhoun VD, Pittman B, Corbera S, Wexler BE, Bell MD, Pelphrey K, Pearlson GD, Assaf M.

Neuroimage Clin. 2019 Aug 1;24:101966. doi: 10.1016/j.nicl.2019.101966. [Epub ahead of print]

2.

Immunity to Respiratory Infection Is Reinforced Through Early Proliferation of Lymphoid TRM Cells and Prompt Arrival of Effector CD8 T Cells in the Lungs.

Suarez-Ramirez JE, Chandiran K, Brocke S, Cauley LS.

Front Immunol. 2019 Jun 14;10:1370. doi: 10.3389/fimmu.2019.01370. eCollection 2019.

3.

Prediction of Membrane Permeation of Drug Molecules by Combining an Implicit Membrane Model with Machine Learning.

Brocke SA, Degen A, MacKerell AD Jr, Dutagaci B, Feig M.

J Chem Inf Model. 2019 Mar 25;59(3):1147-1162. doi: 10.1021/acs.jcim.8b00648. Epub 2018 Dec 27.

PMID:
30540459
4.

Measuring theory of mind in schizophrenia research: Cross-cultural validation.

Lee HS, Corbera S, Poltorak A, Park K, Assaf M, Bell MD, Wexler BE, Cho YI, Jung S, Brocke S, Choi KH.

Schizophr Res. 2018 Nov;201:187-195. doi: 10.1016/j.schres.2018.06.022. Epub 2018 Jun 28.

PMID:
29958750
5.

PDE8 controls CD4+ T cell motility through the PDE8A-Raf-1 kinase signaling complex.

Basole CP, Nguyen RK, Lamothe K, Vang A, Clark R, Baillie GS, Epstein PM, Brocke S.

Cell Signal. 2017 Dec;40:62-72. doi: 10.1016/j.cellsig.2017.08.007. Epub 2017 Aug 26.

PMID:
28851628
6.

Differential Expression and Function of PDE8 and PDE4 in Effector T cells: Implications for PDE8 as a Drug Target in Inflammation.

Vang AG, Basole C, Dong H, Nguyen RK, Housley W, Guernsey L, Adami AJ, Thrall RS, Clark RB, Epstein PM, Brocke S.

Front Pharmacol. 2016 Aug 23;7:259. doi: 10.3389/fphar.2016.00259. eCollection 2016.

7.

Inhibition of breast cancer cell migration by activation of cAMP signaling.

Dong H, Claffey KP, Brocke S, Epstein PM.

Breast Cancer Res Treat. 2015 Jul;152(1):17-28. doi: 10.1007/s10549-015-3445-9. Epub 2015 May 29.

PMID:
26022351
8.

Oral zinc aspartate treats experimental autoimmune encephalomyelitis.

Schubert C, Guttek K, Grüngreiff K, Thielitz A, Bühling F, Reinhold A, Brocke S, Reinhold D.

Biometals. 2014 Dec;27(6):1249-62. doi: 10.1007/s10534-014-9786-8. Epub 2014 Aug 22.

PMID:
25146336
9.

DPP4-directed therapeutic strategies for MERS-CoV.

Reinhold D, Brocke S.

Lancet Infect Dis. 2014 Feb;14(2):100-1. doi: 10.1016/S1473-3099(13)70696-0. No abstract available.

PMID:
24457167
10.

Financial victimization of adults with severe mental illness.

Claycomb M, Black AC, Wilber C, Brocke S, Lazar CM, Rosen MI.

Psychiatr Serv. 2013 Sep 1;64(9):918-20. doi: 10.1176/appi.ps.005882012.

11.

Regulatory T-cells and cAMP suppress effector T-cells independently of PKA-CREM/ICER: a potential role for Epac.

Vang AG, Housley W, Dong H, Basole C, Ben-Sasson SZ, Kream BE, Epstein PM, Clark RB, Brocke S.

Biochem J. 2013 Dec 15;456(3):463-73. doi: 10.1042/BJ20130064.

PMID:
24007532
12.

Expression of phosphodiesterase 6 (PDE6) in human breast cancer cells.

Dong H, Claffey KP, Brocke S, Epstein PM.

Springerplus. 2013 Dec 18;2:680. doi: 10.1186/2193-1801-2-680. eCollection 2013.

13.

Zinc aspartate suppresses T cell activation in vitro and relapsing experimental autoimmune encephalomyelitis in SJL/J mice.

Stoye D, Schubert C, Goihl A, Guttek K, Reinhold A, Brocke S, Grüngreiff K, Reinhold D.

Biometals. 2012 Jun;25(3):529-39. doi: 10.1007/s10534-012-9532-z. Epub 2012 Feb 19.

PMID:
22350510
14.

Peroxisome proliferator-activated receptor gamma is required for CD4+ T cell-mediated lymphopenia-associated autoimmunity.

Housley WJ, Adams CO, Vang AG, Brocke S, Nichols FC, LaCombe M, Rajan TV, Clark RB.

J Immunol. 2011 Oct 15;187(8):4161-9. doi: 10.4049/jimmunol.1101731. Epub 2011 Sep 9.

15.

Divergent actions by inhibitors of DP IV and APN family enzymes on CD4+ Teff cell motility and functions.

Biton A, Ansorge S, Bank U, Täger M, Reinhold D, Brocke S.

Immunobiology. 2011 Dec;216(12):1295-301. doi: 10.1016/j.imbio.2011.07.001. Epub 2011 Jul 7.

PMID:
21802166
16.
17.

PETIR-001, a dual inhibitor of dipeptidyl peptidase IV (DP IV) and aminopeptidase N (APN), ameliorates experimental autoimmune encephalomyelitis in SJL/J mice.

Reinhold D, Bank U, Entz D, Goihl A, Stoye D, Wrenger S, Brocke S, Thielitz A, Stefin S, Nordhoff K, Heimburg A, Täger M, Ansorge S.

Biol Chem. 2011 Mar;392(3):233-7. doi: 10.1515/BC.2011.024.

PMID:
21194377
18.

PDE8 regulates rapid Teff cell adhesion and proliferation independent of ICER.

Vang AG, Ben-Sasson SZ, Dong H, Kream B, DeNinno MP, Claffey MM, Housley W, Clark RB, Epstein PM, Brocke S.

PLoS One. 2010 Aug 9;5(8):e12011. doi: 10.1371/journal.pone.0012011.

19.

Role of dipeptidyl peptidase IV (DP IV)-like enzymes in T lymphocyte activation: investigations in DP IV/CD26-knockout mice.

Reinhold D, Goihl A, Wrenger S, Reinhold A, Kühlmann UC, Faust J, Neubert K, Thielitz A, Brocke S, Täger M, Ansorge S, Bank U.

Clin Chem Lab Med. 2009;47(3):268-74.

PMID:
19676138
20.

Prophylactic and therapeutic suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor.

Kobayashi N, Kiptoo P, Kobayashi H, Ridwan R, Brocke S, Siahaan TJ.

Clin Immunol. 2008 Oct;129(1):69-79. doi: 10.1016/j.clim.2008.06.002. Epub 2008 Aug 3.

21.

Prevention of lipopolysaccharide-induced intussusception in mice by the COX2 inhibitor rofecoxib.

Badriyyah M, Mazeh H, Brocke S, Osmanova V, Freund HR, Hanani M.

Pediatr Surg Int. 2008 Mar;24(3):333-6. Epub 2007 Nov 6.

PMID:
17985132
22.

DP IV/CD26, APN/CD13 and related enzymes as regulators of T cell immunity: implications for experimental encephalomyelitis and multiple sclerosis.

Reinhold D, Bank U, Täger M, Ansorge S, Wrenger S, Thielitz A, Lendeckel U, Faust J, Neubert K, Brocke S.

Front Biosci. 2008 Jan 1;13:2356-63. Review.

PMID:
17981717
23.

Geranylgeranylation but not GTP loading determines rho migratory function in T cells.

Waiczies S, Bendix I, Prozorovski T, Ratner M, Nazarenko I, Pfueller CF, Brandt AU, Herz J, Brocke S, Ullrich O, Zipp F.

J Immunol. 2007 Nov 1;179(9):6024-32.

24.

Dual inhibition of dipeptidyl peptidase IV and aminopeptidase N suppresses inflammatory immune responses.

Reinhold D, Biton A, Goihl A, Pieper S, Lendeckel U, Faust J, Neubert K, Bank U, Täger M, Ansorge S, Brocke S.

Ann N Y Acad Sci. 2007 Sep;1110:402-9. Review.

PMID:
17911455
25.

TGF-beta1-mediated control of central nervous system inflammation and autoimmunity through the inhibitory receptor CD26.

Preller V, Gerber A, Wrenger S, Togni M, Marguet D, Tadje J, Lendeckel U, Röcken C, Faust J, Neubert K, Schraven B, Martin R, Ansorge S, Brocke S, Reinhold D.

J Immunol. 2007 Apr 1;178(7):4632-40.

26.

Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation.

Reinhold D, Biton A, Pieper S, Lendeckel U, Faust J, Neubert K, Bank U, Täger M, Ansorge S, Brocke S.

Int Immunopharmacol. 2006 Dec 20;6(13-14):1935-42. Epub 2006 Aug 17.

PMID:
17161346
27.

CD26/DP IV in T cell activation and autoimmunity.

Preller V, Gerber A, Togni M, Wrenger S, Schraven B, Röcken C, Marguet D, Ansorge S, Brocke S, Reinhold D.

Adv Exp Med Biol. 2006;575:187-93. No abstract available.

PMID:
16700522
28.

Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation.

Biton A, Bank U, Täger M, Ansorge S, Reinhold D, Lendeckel U, Brocke S.

Adv Exp Med Biol. 2006;575:177-86. No abstract available.

PMID:
16700521
29.

Phosphodiesterase 8 (PDE8) regulates chemotaxis of activated lymphocytes.

Dong H, Osmanova V, Epstein PM, Brocke S.

Biochem Biophys Res Commun. 2006 Jun 30;345(2):713-9. Epub 2006 May 3.

PMID:
16696947
30.

Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL.

Aktas O, Smorodchenko A, Brocke S, Infante-Duarte C, Schulze Topphoff U, Vogt J, Prozorovski T, Meier S, Osmanova V, Pohl E, Bechmann I, Nitsch R, Zipp F.

Neuron. 2005 May 5;46(3):421-32.

31.

Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis.

Aktas O, Prozorovski T, Smorodchenko A, Savaskan NE, Lauster R, Kloetzel PM, Infante-Duarte C, Brocke S, Zipp F.

J Immunol. 2004 Nov 1;173(9):5794-800.

32.

Differential usage of VLA-4 and CXCR4 by CD3+CD56+ NKT cells and CD56+CD16+ NK cells regulates their interaction with endothelial cells.

Franitza S, Grabovsky V, Wald O, Weiss I, Beider K, Dagan M, Darash-Yahana M, Nagler A, Brocke S, Galun E, Alon R, Peled A.

Eur J Immunol. 2004 May;34(5):1333-41.

33.

Involvement of CXCR4 and IL-2 in the homing and retention of human NK and NK T cells to the bone marrow and spleen of NOD/SCID mice.

Beider K, Nagler A, Wald O, Franitza S, Dagan-Berger M, Wald H, Giladi H, Brocke S, Hanna J, Mandelboim O, Darash-Yahana M, Galun E, Peled A.

Blood. 2003 Sep 15;102(6):1951-8. Epub 2003 May 1.

34.

Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin.

Aktas O, Waiczies S, Smorodchenko A, Dorr J, Seeger B, Prozorovski T, Sallach S, Endres M, Brocke S, Nitsch R, Zipp F.

J Exp Med. 2003 Mar 17;197(6):725-33. Epub 2003 Mar 10.

35.

The role of dipeptidyl peptidase IV (DP IV) enzymatic activity in T cell activation and autoimmunity.

Reinhold D, Kähne T, Steinbrecher A, Wrenger S, Neubert K, Ansorge S, Brocke S.

Biol Chem. 2002 Jul-Aug;383(7-8):1133-8. Review.

PMID:
12437097
36.

Targeting dipeptidyl peptidase IV (CD26) suppresses autoimmune encephalomyelitis and up-regulates TGF-beta 1 secretion in vivo.

Steinbrecher A, Reinhold D, Quigley L, Gado A, Tresser N, Izikson L, Born I, Faust J, Neubert K, Martin R, Ansorge S, Brocke S.

J Immunol. 2001 Feb 1;166(3):2041-8.

37.

T cell receptor peptides for the vaccination therapy of multiple sclerosis.

Brocke S.

Ernst Schering Res Found Workshop. 2000;(30):167-79. Review. No abstract available.

PMID:
10943323
38.

Dipeptidyl peptidase IV (CD26): role in T cell activation and autoimmune disease.

Reinhold D, Hemmer B, Gran B, Steinbrecher A, Brocke S, Kähne T, Wrenger S, Born I, Faust J, Neubert K, Martin R, Ansorge S.

Adv Exp Med Biol. 2000;477:155-60.

PMID:
10849742
39.

Dipeptidyl peptidase IV in inflammatory CNS disease.

Steinbrecher A, Reinhold D, Quigley L, Gado A, Tresser N, Izikson L, Born I, Faust J, Neubert K, Martin R, Ansorge S, Brocke S.

Adv Exp Med Biol. 2000;477:145-53.

PMID:
10849741
40.
41.

Inhibition of experimental autoimmune encephalomyelitis by a tyrosine kinase inhibitor.

Constantin G, Laudanna C, Brocke S, Butcher EC.

J Immunol. 1999 Jan 15;162(2):1144-9.

42.

Differential display analysis of murine encephalitogenic mRNA.

Jeong MC, Izikson L, Uccelli A, Brocke S, Oksenberg JR.

Int Immunol. 1998 Dec;10(12):1819-23.

PMID:
9885902
43.

Tyrphostin AG490, a tyrosine kinase inhibitor, blocks actively induced experimental autoimmune encephalomyelitis.

Constantin G, Brocke S, Izikson A, Laudanna C, Butcher EC.

Eur J Immunol. 1998 Nov;28(11):3523-9.

44.

In vivo survival of viral antigen-specific T cells that induce experimental autoimmune encephalomyelitis.

Ufret-Vincenty RL, Quigley L, Tresser N, Pak SH, Gado A, Hausmann S, Wucherpfennig KW, Brocke S.

J Exp Med. 1998 Nov 2;188(9):1725-38.

45.

Study of relapsing remitting experimental allergic encephalomyelitis SJL mouse model using MION-46L enhanced in vivo MRI: early histopathological correlation.

Xu S, Jordan EK, Brocke S, Bulte JW, Quigley L, Tresser N, Ostuni JL, Yang Y, McFarland HF, Frank JA.

J Neurosci Res. 1998 Jun 1;52(5):549-58.

PMID:
9632311
46.

Chronic relapsing experimental autoimmune encephalomyelitis: effects of insulin-like growth factor-I treatment on clinical deficits, lesion severity, glial responses, and blood brain barrier defects.

Li W, Quigley L, Yao DL, Hudson LD, Brenner M, Zhang BJ, Brocke S, McFarland HF, Webster HD.

J Neuropathol Exp Neurol. 1998 May;57(5):426-38.

PMID:
9596413
47.

In vivo three-dimensional MR microscopy of mice with chronic relapsing experimental autoimmune encephalomyelitis after treatment with insulin-like growth factor-I.

Xu S, Jordan EK, Li W, Yang Y, Chesnick SA, Webster HD, Brocke S, Quigley L, McFarland HF, Frank JA.

AJNR Am J Neuroradiol. 1998 Apr;19(4):653-8.

48.

Microbial peptides and superantigens in the pathogenesis of autoimmune diseases of the central nervous system.

Brocke S, Hausmann S, Steinman L, Wucherpfennig KW.

Semin Immunol. 1998 Feb;10(1):57-67. Review.

PMID:
9529656
49.

Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis.

Shaw MK, Lorens JB, Dhawan A, DalCanto R, Tse HY, Tran AB, Bonpane C, Eswaran SL, Brocke S, Sarvetnick N, Steinman L, Nolan GP, Fathman CG.

J Exp Med. 1997 May 5;185(9):1711-4.

50.

Experimental autoimmune encephalomyelitis in IL-4-deficient mice.

Liblau R, Steinman L, Brocke S.

Int Immunol. 1997 May;9(5):799-803.

PMID:
9184926

Supplemental Content

Loading ...
Support Center